Business
Rosen, Leading Trial Attorneys, Announces Filing of Securities Class Action Lawsuit Against MEI Pharma, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - MEIP
New York, New York--(Newsfile Corp. - September 4, 2020) -  Rosen Law Firm, a global inve...
About this update from Lithos Group Ltd
[{"type":"text","content":"Rosen, Leading Trial Attorneys, Announces Filing of Securities Class Action Lawsuit Against MEI Pharma, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - MEIPNew York, New York--(Newsfile Corp. - September 4, 2020) -  Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the \"Class Period\"). The lawsuit seeks to recover damages for MEI Pharma investors under the federal securities laws.To join the MEI Pharma class action, go to http://www.rosenlegal.com/cases-register-1919.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) MEI Pharma overstated Pracinostat's potential efficacy as an acute myeloid leukemia (\"AML\"), treatment for the target population; (2) consequently, the Phase 3 Pracinostat Trial was unlikely to meet its primary endpoint of overall survival; (3) all the foregoing, once revealed, was foreseeably likely to have a material negative impact on the Company's financial condition and prospects for Pracinostat; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 9, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1919.html or to discuss your rights or interests regarding this class action, please ...